Diffuse intrinsic pontine glioma

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024
Brain, Type 2, LMD, Legislation, Incidence, C-peptide, Cancer, SNY, Panobinostat, GBM, Letter, Trial of the century, Neoplasm, CFO, Diffusion, Cell proliferation, Central nervous system, Apoptosis, Type 1 diabetes, Patent, Breast, Metabolism, Diffuse intrinsic pontine glioma, Type 2 diabetes, Survival, DIPG, MGMT, Patient, Toxicology, Glioblastoma, Tolimidone, Pfizer, Insulin, OXPHOS, Plasma, Oxidative phosphorylation, FDA, Progression-free survival, Convection, Columbia University, Type 1, Cerebrospinal fluid, DMG, Pharmaceutical industry

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Slalom Collaborates with AWS and DIPG DMG Research Funding Alliance to Fight Childhood Brain Cancer with Data

Retrieved on: 
Thursday, December 14, 2023
Neoplasm, AWS, Diffusion, Caregiver, Mevalonate pathway, DMG, Research, Slalom, Parent, Disease, Cancer, Life expectancy, Brain, Death, Diffuse intrinsic pontine glioma, Ward, Child, DIPG, Central nervous system, Diagnosis, Amazon Web Services, Pharmaceutical industry

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).

Key Points: 
  • SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- In a united effort to combat childhood brain cancer, Slalom has worked with Amazon Web Services (AWS) and the DIPG DMG Research Funding Alliance (DDRFA) to create the DIPG One Link , a unique centralized resource hub that helps accelerate research and awareness of Diffuse Intrinsic Pontine Glioma (DIPG), also known as Diffuse Midline Glioma (DMG).
  • DIPG DMG is a rare and often fatal form of childhood brain cancer with limited treatment options and scarce research data.
  • “As parents fighting DIPG alongside our children we discovered significant gaps in the system which expects parents to navigate their child’s care.
  • With AWS, Slalom executed the research, design, and development of the DIPG One Link website to support those looking for information to fight DIPG DMG.

SonALAsense Presents Preliminary Data From Clinical Study in Patients With Deadly Pediatric Brain Tumor

Retrieved on: 
Wednesday, December 13, 2023
Surgery, Medical Devices, Neurology, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Oncology, SDT, Radiation, Hope, Pakistan Society of Neuro-Oncology, Sonodynamic therapy, Patient, Aminolevulinic acid, Death, Diffusion, Steroid, Incisionless Fritsch otoplasty, Neurosurgery, Hydrogen chloride, Diagnosis, Survival, Diffuse intrinsic pontine glioma, Infrared spectroscopy correlation table, Quality of life, DIPG, SNO, Metastasis, Medical imaging, Pharmaceutical industry, Development

These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.

Key Points: 
  • These results were presented at the November 2023 Society for Neuro-Oncology (SNO) Annual Meeting in Vancouver, Canada.
  • The preliminary data from Study SDT-201 shows signals of clinical activity and no safety concerns.
  • Study SDT-201 is a dose escalation and expansion study in patients with DIPG.
  • Six (6) patients have been treated to date and dose escalation is ongoing.

Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors

Retrieved on: 
Tuesday, December 5, 2023
Other Health, Research, Pharmaceutical, Oncology, Consumer, Hospitals, Children, Clinical Trials, Science, Biotechnology, Other Science, Health, CNS, Juno Therapeutics, Seattle Children's, Bristol Myers Squibb, Safety, Brainchild, Therapy, Glioblastoma, Brain, Leukemia, Patient, Multimedia, GSK, Neoplasm, Child, Diffuse intrinsic pontine glioma, Cancer, R, Transgene, Immunotherapy, Lymphoma, Central nervous system, Pharmaceutical industry, DIPG

Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.

Key Points: 
  • Seattle Children's today announced the launch of BrainChild Bio, Inc. to accelerate the advancement of chimeric antigen receptor (CAR) T-cell therapies in Central Nervous System (CNS) tumors.
  • BrainChild Bio will be granted an exclusive license to novel CAR T-cell technology for CNS tumors developed at Seattle Children’s and will build upon the pioneering CAR T-cell therapy and clinical translational work of Michael Jensen, M.D., and his team at Seattle Children’s Therapeutics.
  • Seattle Children’s has provided the initial equity funding for BrainChild Bio which will operate as an independently managed corporation.
  • The launch of BrainChild Bio is a natural progression of Seattle Children’s Therapeutics’ goal to expand access to potentially life-changing therapies through collaborations with biotech companies.

FDA Grants Fast Track Designation to SonALAsense’s SONALA-001 in Combination with the INSIGHTEC Transcranial Ultrasound Device for Sonodynamic Therapy of DIPG, a Rare Pediatric Brain Cancer

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, FDA, Medical Devices, Neurology, Clinical Trials, Biotechnology, Brain, SDT, Safety, Annual general meeting, Radiation, ALA, Pons, Pakistan Society of Neuro-Oncology, Plasma protein binding, Collection, Sonodynamic therapy, Patient, Heart rate, Light, NCT, Hydrogen chloride, Diffuse intrinsic pontine glioma, Survival, Diagnosis, Trial of the century, Communication, Biomarker, DIPG, SNO, Spinal cord, Blood pressure, Pharmaceutical industry, Development

This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.

Key Points: 
  • This builds upon SONALA-001 also having received orphan drug designation in 2021 for malignant gliomas.
  • The FDA’s Fast Track is a process designed to facilitate the development, and expedited review, of drugs to treat serious conditions and fill an unmet medical need.
  • “Receiving Fast Track Designation underscores the immediate and urgent need to bring new therapy options for DIPG patients,” said Ely Benaim, M.D., SonALAsense’s Chief Medical Officer and Executive Vice President of Development.
  • Approximately 300 children are diagnosed with DIPG each year in the US, usually between the ages of 5 and 9.

Pioneer Launches Venture Group to Fund the Fight Against Rare Pediatric Brain Cancer

Retrieved on: 
Wednesday, December 6, 2023
Arm, Attention, Koenen, Research, CD200, Radiation, Immune system, Therapy, Pediatrics, University, Glioblastoma, Diffuse intrinsic pontine glioma, OX2, FDA, Child, Peter Westerhaus, MD, Diagnosis, Pioneer, Doctor of Philosophy, Immunotherapy, DIPG, Children's Hospital, Mutation, Cell, Life, Hospital, Pharmaceutical industry, Birth control, Charles Moertel

"We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.

Key Points: 
  • "We've been working to start a venture arm for more than five years now," said Pioneer founder and co-owner, Brian Westerhaus.
  • (Koenen is a partner and co-owner at Pioneer Management Consulting and Pioneer Ventures Group.)
  • It gets less than 4% of all cancer research dollars available, and almost none of that goes to rare types, like DIPG.
  • To donate to the pediatric trial at Children's Hospital in Minnesota, please contact Teri Cannon [email protected]

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

Retrieved on: 
Tuesday, November 7, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survival, Research, Research and development, Trial of the century, IND, NYSE, Food, DCR, Enrollment, Form, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, CPI, Investigational New Drug, DCR Workforce, Diffuse intrinsic pontine glioma, Cancer, Central nervous system, Lung cancer, TMZ, Patient, Drug discovery, Potential, Administration, DIPG, Pharmaceutical industry, Mobile phone, Medical imaging, Cryptocurrency, NSCLC, Glioma

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.

Key Points: 
  • MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, today reported financial results for the third quarter ended September 30, 2023 and key operational updates.
  • Research and Development (R&D) Expenses: R&D expenses were approximately $2.6 million for the quarter ended September 30, 2023, compared to approximately $2.3 million for quarter ended September 30, 2022.
  • Weighted average shares outstanding were 13,675,802 in the third quarter of 2023, compared to 10,165,622 in the third quarter of 2022.
  • For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.

MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

Retrieved on: 
Thursday, October 12, 2023
Research, Children, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Consumer, Health, Science, Oncology, NYSE, Diffuse intrinsic pontine glioma, Central nervous system, Immunity, DNA, Neuro-Oncology (journal), Diffusion, Cancer, Society, Immunotherapy, IR, Radiation therapy, Neoplasm, Conference, Medical imaging, Vaccine, DIPG

MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.

Key Points: 
  • MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, announced that study data shows THIO’s potent anticancer activity in Diffuse Intrinsic Pontine Glioma (DIPG), one of the most aggressive tumors affecting the central nervous system in children.
  • The data was recently presented at the Society for Neuro-Oncology’s 2023 Pediatric Neuro-Oncology Research Conference and published in the Neuro-Oncology journal (Volume 25, Issue Supplement_1, June 2023, Page i13) .
  • Radiotherapy is the only standard of care treatment option for DIPG, yet it is rarely curative.
  • However, the low mutational burden and rare infiltration of T lymphocytes renders these tumors immunologically “cold” and, therefore, poses challenges for general immunotherapy.

KAZIA THERAPEUTICS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT AND ORAL PRESENTATION OF PNOC022 CLINICAL DATA AT 2023 SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING

Retrieved on: 
Friday, September 29, 2023
Society, Education, SNO, EST, Diffuse intrinsic pontine glioma, Pakistan Society of Neuro-Oncology, Research, KZIA, DIPG, Annual general meeting, PNOC, Health, DMG Mori Aktiengesellschaft, Pharmaceutical industry

SNO exists to advance multi-disciplinary brain tumour research, education, and collaboration to drive discovery and improve patient care.

Key Points: 
  • SNO exists to advance multi-disciplinary brain tumour research, education, and collaboration to drive discovery and improve patient care.
  • The 28th Annual Meeting of the Society for Neuro-Oncology will take place from November 15 - 19, 2023 in Vancouver, Canada.
  • Kazia Chief Executive Officer, Dr John Friend commented, "The Society for Neuro-Oncology conference is a high-profile meeting where many of the best ideas are discussed in brain tumour research.
  • We are very excited that the abstract from the PNOC022 study has been selected for oral presentation in this forum and look forward to sharing data with our shareholders and the market in due course."

EMulate Therapeutics Announces the Publication of Its Phase I/II Results in CNS Oncology: “An Expanded Safety/Feasibility Study of the EMulate Therapeutics Voyager™ System in Patients with Recurrent Glioblastoma”

Retrieved on: 
Wednesday, July 19, 2023
Oncology, Medical Devices, Health, Clinical Trials, Radiology, Biotechnology, Cancer Institute, GBM, Providence, Doctor of Philosophy, Glioblastoma, Humanitarian Device Exemption, Emulate, DIPG, Journal, MD, Patient, Diffuse intrinsic pontine glioma, FDA, Therapy, Pharmaceutical industry

EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016 .

Key Points: 
  • EMulate Therapeutics, Inc. (EMulate) announced today the publication of its peer-reviewed clinical trial using EMulate’s technology for the treatment of glioblastoma in the Journal CNS Oncology https://www.futuremedicine.com/doi/10.2217/cns-2022-0016 .
  • This marks an ongoing and developing pathway in the development of EMulate’s oncology treatment business.
  • “These results are pivotal for EMulate as we continue to develop, optimize and expand our technology’s use and value,” stated Chris Rivera, EMulate’s President and CEO.
  • We are also planning to initiate a pivotal Phase III study in these indications in early 2024.”